Quell Therapeutics
Quell Therapeutics is a London-based biotech developing cell therapies for organ transplants and autoimmune diseases. The company has raised $285M, including a Series B in late 2021, and employs 113 people.
The growth story
Quell Therapeutics grew from 76 to 113 employees between 2021 and 2026, raising $285M along the way, most recently a Series B in November 2021.
About
Quell Therapeutics develops cell-based immunotherapies targeting solid organ transplantation and autoimmune conditions. Its treatments aim to modulate immune responses to improve patient outcomes in these areas.
The company has scaled rapidly since its 2019 founding, reaching 113 employees and securing $285M in funding. Its Series B round in late 2021 included major investors like Fidelity and Point72, signaling strong institutional backing for its therapeutic approach.
Founders and leadership
Research is Quell's largest function, accounting for 41 of its 113 employees. The company operates with a median tenure of 2 years, suggesting a relatively young organization still building out its leadership and expertise.
The Quell Therapeutics org chart
Iain McGill (CEO) leads 46 mapped leaders with 6 direct reports. Click +N to expand a team; names link to the person’s public profile.
Departments, and which ones grew
Headcount by function: Research 53 (-35% YoY), Business Development 9 (-25% YoY), Quality Assurance 9 (-25% YoY), Operations 7 (-12% YoY), Finance 5 (-29% YoY), Administrative 4 (-20% YoY).
Talent flow
Quell recruits heavily from Imperial College London and GSK, with 15 and 13 hires respectively. Its alumni frequently move to AstraZeneca and Vertex Pharmaceuticals, indicating strong industry recognition of its talent pool.
Most common previous employers of Quell Therapeutics staff: Imperial College London (15), GSK (13), Achilles Therapeutics (12), King's College London (10), UCL (7), Autolus Therapeutics (6). Former Quell Therapeutics employees most often moved to AstraZeneca (5), Vertex Pharmaceuticals (3), Orchard Therapeutics - U.S. (3), Autolus Therapeutics (3), IMU Biosciences (3), UCL (3).
Alumni worth knowing
The Quell Therapeutics mafia
Quell alumni have founded 5 companies, including Coding Bio (23 employees) and Wasteless Bio (8 employees). This entrepreneurial activity suggests the company fosters innovation and leadership development.
5Simon Bornschein, was CAR-T engineer until 2020Matej Metkovic, was Research Associate until 2021Nia Emami, was Associate Director - Product Research until 2022Adam B., was Senior Manager IT Operations until 2025Nathalie Clerget, was VP clinical operations until 2024Web traffic
Traffic mix: 40% direct, 44% search, 7% social, 1% paid.
What this company is made of
Most common skills at Quell Therapeutics: Cell Culture (37), Flow Cytometry (35), Leadership (32), Research Skills (29), Molecular Biology (27), Communication (27), Microsoft Excel (27), Data Analysis (26).
Where the team actually sits
Quell Therapeutics people are concentrated in England, United Kingdom (59), United Kingdom (26), London Area, United Kingdom (11), Pennsylvania, United States (1).
Search footprint
Quell Therapeutics attracts about 197 organic search visits a month, traffic worth roughly $1K a month if bought through ads. It gained 32 ranking keywords and lost 30 in the last period.
What employees say
- Compensation
- 3.40 / 5
- Career opportunities
- 2.60 / 5
- Senior management
- 2.90 / 5
- Work-life balance
- 3.00 / 5
Frequently asked
Quell Therapeutics has 113 employees as of September 2026.
Quell Therapeutics has raised $285M in total, most recently a Series B round in November 2021.
Quell Therapeutics was founded in 2019 by Marc Martinez-Llordella.
Iain McGill (CEO) sits at the top of Quell Therapeutics's reporting structure, with 6 direct reports.
The most common previous employers of current Quell Therapeutics staff are Imperial College London (15 people), GSK (13 people), Achilles Therapeutics (12 people).
Former Quell Therapeutics employees most often move to AstraZeneca (5), Vertex Pharmaceuticals (3), Orchard Therapeutics - U.S. (3).
At least 5 companies have a founder who previously worked at Quell Therapeutics, including Coding Bio, Wasteless Bio, Fortitude Consulting.
Quell Therapeutics attracts about 197 organic search visits a month, worth roughly $1K a month in equivalent ad spend.
The most common skills among Quell Therapeutics staff are Cell Culture, Flow Cytometry, Leadership, Research Skills, Molecular Biology.
Quell Therapeutics staff are concentrated in England, United Kingdom (59), United Kingdom (26), London Area, United Kingdom (11).
Quell Therapeutics has about 53 people in Research, down 35% over the past year, as of September 2026.
Quell Therapeutics has about 9 people in Business Development, down 25% over the past year, as of September 2026.
Computed from 101 current and 159 former Quell Therapeutics profiles, as of September 2026. Source: Crustdata.
Build this for any company
Every number on this page came from the Crustdata API. Point the MCP at a company and get the same org chart, alumni list and talent flow in one prompt.